Immix Biopharma, Inc. financial data

Symbol
IMMX on Nasdaq
Industry
Pharmaceutical Preparations
Location
11400 West Olympic Blvd., Suite 200, Los Angeles, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 636 % -39.5%
Debt-to-equity 20.7 % +81.4%
Return On Equity -87.1 % -4.76%
Return On Assets -72.1 % +3.39%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.5M shares +68.5%
Common Stock, Shares, Outstanding 27.4M shares +68.7%
Entity Public Float 28M USD +52.8%
Common Stock, Value, Issued 2.75K USD +68.4%
Weighted Average Number of Shares Outstanding, Basic 28.8M shares +91.4%
Weighted Average Number of Shares Outstanding, Diluted 28.8M shares +91.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 20M USD
Research and Development Expense 10.7M USD +64.6%
General and Administrative Expense 9.51M USD +87.2%
Operating Income (Loss) -20.2M USD -74.5%
Nonoperating Income (Expense) 990K USD +138%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.2M USD -68.3%
Income Tax Expense (Benefit) 34K USD +84.3%
Net Income (Loss) Attributable to Parent -19M USD -67%
Earnings Per Share, Basic -0.84 USD/shares -5%
Earnings Per Share, Diluted -0.84 USD/shares +37.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24M USD +89.5%
Other Assets, Current 106K USD
Assets, Current 27.3M USD +76.2%
Property, Plant and Equipment, Net 454K USD +17712%
Operating Lease, Right-of-Use Asset 1.03M USD
Other Assets, Noncurrent 20.4K USD -64%
Assets 28.8M USD +85.2%
Accounts Payable, Current 2.35M USD
Employee-related Liabilities, Current 171K USD
Liabilities, Current 3.9M USD +62.9%
Operating Lease, Liability, Noncurrent 1.04M USD
Liabilities 4.94M USD +106%
Accumulated Other Comprehensive Income (Loss), Net of Tax 117K USD +44.6%
Retained Earnings (Accumulated Deficit) -63.1M USD -43.2%
Stockholders' Equity Attributable to Parent 23.9M USD +80.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 23.9M USD +81.4%
Liabilities and Equity 28.8M USD +85.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83M USD -82.9%
Net Cash Provided by (Used in) Financing Activities 15.9M USD +13312%
Net Cash Provided by (Used in) Investing Activities -302K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 27.5M shares +68.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11.8M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 80 USD
Deferred Tax Assets, Valuation Allowance 7.63M USD +126%
Operating Lease, Liability 1.09M USD
Depreciation 3.01K USD +496%
Payments to Acquire Property, Plant, and Equipment 302K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19M USD -66.4%
Lessee, Operating Lease, Liability, to be Paid 1.6M USD
Property, Plant and Equipment, Gross 64.5K USD 0%
Operating Lease, Liability, Current 48.4K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 153K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 148K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 513K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 158K USD
Deferred Tax Assets, Operating Loss Carryforwards 4.08M USD +113%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 86.9M USD +51.8%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 590K USD +167%
Interest Expense 98.9K USD -99.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%